WO2004099132A2 - Process for the preparation of trans-isomers of diphenylazetidinone derivatives - Google Patents

Process for the preparation of trans-isomers of diphenylazetidinone derivatives Download PDF

Info

Publication number
WO2004099132A2
WO2004099132A2 PCT/IB2004/001396 IB2004001396W WO2004099132A2 WO 2004099132 A2 WO2004099132 A2 WO 2004099132A2 IB 2004001396 W IB2004001396 W IB 2004001396W WO 2004099132 A2 WO2004099132 A2 WO 2004099132A2
Authority
WO
WIPO (PCT)
Prior art keywords
formula
chiral
ether
reaction
carried out
Prior art date
Application number
PCT/IB2004/001396
Other languages
French (fr)
Other versions
WO2004099132A3 (en
Inventor
Kiran Kumar Ganagakhedkar Shubham Karooti
Parendu Dhirajlal Rathod
Ram Chander Aryan
Yatendra Kumar
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to EP04731224A priority Critical patent/EP1626954A2/en
Publication of WO2004099132A2 publication Critical patent/WO2004099132A2/en
Publication of WO2004099132A3 publication Critical patent/WO2004099132A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Definitions

  • the field of the invention relates to processes for the preparation of trans-isomers of diphenylazetidinone derivatives, using a chiral delta-lactone. It also relates to processes for the preparation of the chiral delta-lactone. The invention also relates to pharmaceutical compositions that include the trans-isomers of diphenylazetidinone derivatives.
  • Diphenylazetidinone derivatives such as ezetimibe are useful as hypocholesterolemic agents, for the prevention and treatment of atherosclerosis.
  • Several processes have been reported for the preparation of diphenylzetidinones for example, in U.S. Patent Nos. 5,631,365; 5,886,171; 6,207,822; 6,133,001; and 5,856,473.
  • R 1 and R 2 are identical or different, and represent hydrogen, halogen or an alkoxy group, and R 3 represents hydrogen, alkyl or a hydroxy protecting group.
  • the process includes reacting a chiral delta-lactone of formula II,
  • R , and R are as defined above, in the presence of a base.
  • R 1 and R are as defined above; and hydrolyzing the chiral hydroxyester to obtain the chiral hydroxyacid of formula IN.
  • a pharmaceutical composition that includes a therapeutically effective amount of trans-isomer of a diphenylazetidinone derivative or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable carriers, excipients or diluents.
  • the inventors have developed an efficient process for the preparation of trans- isomers of diphenylazetidinone of formula I, or a salt thereof, wherein R 1 and R 2 are identical or different, and represent hydrogen, halogen or an alkoxy group, and R 3 represents hydrogen, alkyl or a hydroxy protecting group.
  • the process involves reacting a chiral delta-lactone of formula II, with a diphenyl imine of formula III, in the presence of a base, wherein R 1 , R 2 and R 3 are as defined above.
  • halogen includes fluorine, chlorine, bromine, and iodine.
  • hydroxy protecting groups include aralkyl such as benzyl, alkyl such as methyl and ethyl, alkoxyalkyl such as methoxymethyl, and trialkylsilyl such as trimethylsilyl and tert- butyldimethylsilyl groups.
  • alkyl groups include methyl, ethyl, n-propyl,
  • R and R represent fluorine and R 3 represents hydrogen in the compounds of formula I.
  • Examples of a base which can be used in the reaction of chiral delta-lactone of formula II with diphenyl imine of formula III include an alkyl lithium such as n-butyl- lithium, a metal hydride such as sodium hydride, a metal alkoxide such as sodium methoxide, and a metal amide such as sodium bistrimethylsilylamide, potassium bistrimethylsilylamide, lithium bistrimethylsilylamide, lithium dicyclohexylamide and lithium diisopropylamide.
  • the reaction may be carried out at a temperature from about -100°C to about 50°C, for example at a temperature from about -80°C to about 0°C. hi particular, it may be carried out at a temperature from about -60°C to about -40°C.
  • Suitable solvents for reaction of the compounds of formula II with compounds of formula III are inert organic solvents that do not change under the reaction conditions.
  • solvents include ethers, such as dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran (THF); chlorinated hydrocarbons such as methylene dichloride and ethylene dichloride; hydrocarbons such as hexane, cyclohexane, toluene, and xylene; dipolar aprotic solvents such as dimethylformamide, dimethyl sulphoxide, N- methylpyrrolidone; and mixtures thereof.
  • ethers such as dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran (THF); chlorinated hydrocarbons such as methylene dichloride and ethylene dichloride; hydrocarbons such as hexane, cyclohexane
  • Cosolvents such as hexamethylphosphoramide (HMPA), Hexamethyl phosphorus triamide (HMPT), N,N-dimethylimidazolidinone (DMI) and l,3-dimethyl-3 ,4,5,6- tetrahydro-2-(lH)-pyrimidinone (DMPU) may also be added.
  • HMPA hexamethylphosphoramide
  • HMPT Hexamethyl phosphorus triamide
  • DI N,N-dimethylimidazolidinone
  • DMPU l,3-dimethyl-3 ,4,5,6- tetrahydro-2-(lH)-pyrimidinone
  • the reaction can be quenched by an acid such as acetic acid or hydrochloric acid, and the trans azetidinones of formula I can be recovered by extraction followed by crystallization or column chrornatography.
  • an acid such as acetic acid or hydrochloric acid
  • the hydroxy substituent present in the imine intermediate of formulas III can be protected.
  • a protecting group is present, an additional step comprising removal of the protecting group by conventional techniques is needed.
  • the protecting group is a benzyloxy group
  • a debenzylation reaction with a hydrogenating agent such as palladium on carbon and ammonium formate can be conducted; an alkoxy group can be converted to a hydroxy group by treatment with a Lewis acid, and a silyl protecting groups can be removed by treatment with fluoride, to obtain a compound of formula I wherein R 3 is hydrogen.
  • the diphenylimines of formula III can be prepared from suitably substituted benzaldehydes and anilines by procedures well known in the art.
  • Trans-isomers of diphenylazetidinones of formula I can form alkali metal salts at the phenolic hydroxyl position.
  • the salt can be prepared by contacting the diphenylazetidinone of formula I with a sufficient amount of alkali metal hydroxides such as sodium hydroxide or potassium hydroxide, alkali metal carbonates such as sodium carbonate or potassium carbonate, alkali metal hydrides such as sodium hydride, or alkali metal bicarbonates such as sodium bicarbonate in a suitable solvent.
  • the inventors have also developed a process for the preparation of the chiral delta- lactone of formula II, wherein R 1 represents hydrogen, halogen or an alkoxy group.
  • the process involves cyclizing a chiral hydroxyacid of formula IN in the presence of an acid or a salt of a weak base to obtain the chiral lactone of formula II.
  • a weak base Both organic and inorganic acids may be used.
  • suitable acids include hydrochloric, p-toluenesulfonic, acetic, and methanesulfonic acids.
  • suitable salts of a weak base include pyridinium p-toluenesulfonate, and pyridine hydrobromide.
  • the cyclization reaction may be carried out at a temperature from about -20°C to about 120°C, or at a temperature from about 0°C to about 60°C. In particular, it may be carried out at a temperature from about 10°C to about 40°C.
  • the cyclization reaction may be carried out in a suitable solvent.
  • suitable solvent includes any solvent or solvent mixtures which are inert and do not change under the reaction conditions, may be used in the cyclization reactions.
  • solvents include ethers such as diethyl ether, dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran; chlorinated hydrocarbons such as methylene dichloride and ethylene dichloride; esters such as ethyl acetate and isopropyl acetate; ketones such as acetone and methylisobutylketone (MLBK); hydrocarbons such as hexane, toluene, and xylene; acetonitrile; dipolar aprotic solvents such as dimethylfo ⁇ namide, dimethylsulphoxide, N-methylpyrrolidone, sulpholane; and mixtures thereof.
  • ethers such as diethyl ether, dibutyl ether, methyl tert-butyl
  • the inventors have also developed a process for the preparation of chiral hydroxyacid of formula IN, wherein R 1 represents hydrogen, halogen or an alkoxy group.
  • the process involves stereoselectively reducing benzoyl butyrate of formula NI, wherein R 1 represents hydrogen, halogen or an alkoxy group, and R is an alkyl group, to obtain chiral hydroxyester of formula N; and hydrolyzing the resulting chiral hydroxyester of formula N.
  • the stereoselective reduction of the compound of formula NI to the compound of formula N may be achieved by reduction with a chiral reducing agent or by using a reducing agent in the presence of a chiral catalyst.
  • chiral reducing agents used for the reduction are those customarily used in organic chemistry.
  • chiral reducing agents include chiral boranes such as (-)- ⁇ 3-chlorodiisopinocampheylborane (DIP-Cl), (S)-BI ⁇ AP, (S)-BINAL-H and compounds of structures as shown below:
  • reducing agents include sodium borohydride, sodium cyanoborohydride and a borane complex such as borane-THF, and borane-dimethylsulfide complex.
  • Examples of chiral catalysts which may be used with the above reducing agents can be the same as the chiral boranes exemplified above as chiral reducing agents.
  • the addition of a dilute acid, such as hydrochloric acid, followed by extraction with a suitable solvent produces the compounds of formula V.
  • the reduction temperature may be varied depending on the choice of a catalyst and/or a reducing agent employed. For example, the reduction may be carried out at a temperature range from about -80°C to about 100°C, or at a temperature from about -40°C to about 40°C. i particular, it may be carried out at a temperature from about -25°C to about -10°C.
  • Suitable solvents for reduction of the compounds of formula VI are the customary inert solvents that do not change under the reaction conditions.
  • solvents include ethers, such as dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran; chlorinated hydrocarbons such as methylene dichloride and ethylene dichloride; alcohols such as methanol, ethanol and isopropanol; esters such as ethyl acetate and isopropyl acetate; hydrocarbons such as hexane, toluene, and xylene; dipolar aprotic solvents such as dimethylformamide, dimethyl sulphoxide, N-methylpyrrolidone; and mixtures thereof.
  • ethers such as dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran
  • chlorinated hydrocarbons such as methylene dichloride and
  • the compounds of formula VI can be prepared by conventional esterification of the corresponding acids with suitable alcohols. These acids are known compounds, and can be produced by methods known in the art such as the procedure disclosed in U.S. Patent No. 6,207,822.
  • the compounds of formula IN and formula N may be isolated during the reaction, or allowed to react further in situ to form the chiral lactone of formula II.
  • the 4-(4-fluorobenzoyl)butyric acid (lOOg, 0.476mol) obtained in example 1 was dissolved in 1050ml of methanol and 100ml of 16% methanolic hydrochloric acid was added. The reaction was monitored to completion by TLC and the solvent was evaporated under vacuum. The residue was taken-up in 400ml dichloromethane and washed twice with 250ml of 5% sodium bicarbonate solution and then with 500ml of saturated brine solution. The organic layer was dried over sodium sulfate and evaporated to dryness under reduced pressure. The residue was crystallized from ethyl acetate and hexane to yield the pure product (85.7g, yield: 80%).
  • reaction mass was then poured into a 500ml mixture of methylene chloride and satd. sodium bicarbonate solution (3:2).
  • the aqueous layer was separated and washed with 200ml of methylene chloride and acidified to pH ⁇ 2 at 0°C with 6M hydrochloric acid.
  • the aqueous layer was saturated with sodium chloride and extracted twice with ethyl acetate (200ml).
  • the organic layer was dried over sodium sulfate and evaporated to dryness under reduced pressure. The residue was taken in 11 of toluene and treated with a solution of pyridinium 4-toluenesulfonate (5.7g, lOmol %) dissolved in 200ml methylenechloride.
  • the intermediate trans l-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3- hydroxypropyl]-4-(4-benzyloxyphenyl)-2-azetidinone (5g, lmmol) was dissolved in 85ml methanol and the solution was deaerated. Ammonium formate (6.3 lg, lOmmol), 10%) palladium on carbon (3.6g) and formic acid (0.5ml) was added to the solution. The reaction was heated to 55°C and monitored to completion by TLC. The reaction mixture was filtered over a filtration aid to remove the 'palladium on carbon' and washed with methanol.

Abstract

The invention relates to processes for the preparation of trans-isomers of diphenylazetidinone derivatives of formula (I), using a chiral delta-lactone. It also relates to processes for the preparation of the chiral delta-lactone. The invention also relates to pharmaceutical compositions that include the trans-isomers of diphenylazetidinone derivatives.

Description

PROCESS FOR THE PREPARATION OF TRANS-ISOMERS OF DIPHENYLAZETIDINONE DERIVATIVES
Field of the Invention
The field of the invention relates to processes for the preparation of trans-isomers of diphenylazetidinone derivatives, using a chiral delta-lactone. It also relates to processes for the preparation of the chiral delta-lactone. The invention also relates to pharmaceutical compositions that include the trans-isomers of diphenylazetidinone derivatives.
Background of the Invention
Diphenylazetidinone derivatives such as ezetimibe are useful as hypocholesterolemic agents, for the prevention and treatment of atherosclerosis. Several processes have been reported for the preparation of diphenylzetidinones for example, in U.S. Patent Nos. 5,631,365; 5,886,171; 6,207,822; 6,133,001; and 5,856,473.
Summary of the Invention
In one general aspect there is provided a process for preparing trans-isomers of diphenylazetidinone of formula I, or a salt thereof,
Figure imgf000002_0001
Formula I
wherein R1 and R2 are identical or different, and represent hydrogen, halogen or an alkoxy group, and R3 represents hydrogen, alkyl or a hydroxy protecting group. The process includes reacting a chiral delta-lactone of formula II,
Figure imgf000003_0001
Formula II wherein R1 is as defined above, with a diphenyl imine of formula III,
Figure imgf000003_0002
Formula III
wherein R , and R are as defined above, in the presence of a base.
In another general aspect there is provided a process for preparing the chiral delta- lactone of formula II, wherein R1 is as defined above. The process includes cyclizing a chiral hydroxyacid of formula IN,
Figure imgf000003_0003
Formula IV wherein R1 is as defined above, in the presence of an acid or a salt of a weak base.
In another general aspect there is provided a process for preparing the chiral hydroxyacid of formula IN, wherein R1 is as defined above. The process includes stereoselectively reducing benzoyl butyrate of formula NI,
Figure imgf000004_0001
Formula VI wherein R1 is as defined above, and R is an alkyl group to obtain chiral hydroxyester of formula V,
Figure imgf000004_0002
Formula V
wherein R1 and R are as defined above; and hydrolyzing the chiral hydroxyester to obtain the chiral hydroxyacid of formula IN.
In another general aspect there is provided a pharmaceutical composition that includes a therapeutically effective amount of trans-isomer of a diphenylazetidinone derivative or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable carriers, excipients or diluents.
The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.
Detailed description of the Invention
The inventors have developed an efficient process for the preparation of trans- isomers of diphenylazetidinone of formula I, or a salt thereof, wherein R1 and R2 are identical or different, and represent hydrogen, halogen or an alkoxy group, and R3 represents hydrogen, alkyl or a hydroxy protecting group. The process involves reacting a chiral delta-lactone of formula II, with a diphenyl imine of formula III, in the presence of a base, wherein R1, R2 and R3 are as defined above. The term "halogen" includes fluorine, chlorine, bromine, and iodine. Examples of hydroxy protecting groups include aralkyl such as benzyl, alkyl such as methyl and ethyl, alkoxyalkyl such as methoxymethyl, and trialkylsilyl such as trimethylsilyl and tert- butyldimethylsilyl groups. Examples of alkyl groups include methyl, ethyl, n-propyl,
1 9 isopropyl, and tert-butyl groups, h a particular example, R and R represent fluorine and R3 represents hydrogen in the compounds of formula I.
Examples of a base which can be used in the reaction of chiral delta-lactone of formula II with diphenyl imine of formula III include an alkyl lithium such as n-butyl- lithium, a metal hydride such as sodium hydride, a metal alkoxide such as sodium methoxide, and a metal amide such as sodium bistrimethylsilylamide, potassium bistrimethylsilylamide, lithium bistrimethylsilylamide, lithium dicyclohexylamide and lithium diisopropylamide.
The reaction may be carried out at a temperature from about -100°C to about 50°C, for example at a temperature from about -80°C to about 0°C. hi particular, it may be carried out at a temperature from about -60°C to about -40°C.
Suitable solvents for reaction of the compounds of formula II with compounds of formula III are inert organic solvents that do not change under the reaction conditions. Examples of such solvents include ethers, such as dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran (THF); chlorinated hydrocarbons such as methylene dichloride and ethylene dichloride; hydrocarbons such as hexane, cyclohexane, toluene, and xylene; dipolar aprotic solvents such as dimethylformamide, dimethyl sulphoxide, N- methylpyrrolidone; and mixtures thereof.
Cosolvents such as hexamethylphosphoramide (HMPA), Hexamethyl phosphorus triamide (HMPT), N,N-dimethylimidazolidinone (DMI) and l,3-dimethyl-3 ,4,5,6- tetrahydro-2-(lH)-pyrimidinone (DMPU) may also be added.
The reaction can be quenched by an acid such as acetic acid or hydrochloric acid, and the trans azetidinones of formula I can be recovered by extraction followed by crystallization or column chrornatography.
Those skilled in the art will recognize that for the reaction to proceed as desired, the hydroxy substituent present in the imine intermediate of formulas III can be protected. When a protecting group is present, an additional step comprising removal of the protecting group by conventional techniques is needed. For example, when the protecting group is a benzyloxy group, a debenzylation reaction with a hydrogenating agent such as palladium on carbon and ammonium formate can be conducted; an alkoxy group can be converted to a hydroxy group by treatment with a Lewis acid, and a silyl protecting groups can be removed by treatment with fluoride, to obtain a compound of formula I wherein R3 is hydrogen.
The diphenylimines of formula III can be prepared from suitably substituted benzaldehydes and anilines by procedures well known in the art.
Trans-isomers of diphenylazetidinones of formula I can form alkali metal salts at the phenolic hydroxyl position. The salt can be prepared by contacting the diphenylazetidinone of formula I with a sufficient amount of alkali metal hydroxides such as sodium hydroxide or potassium hydroxide, alkali metal carbonates such as sodium carbonate or potassium carbonate, alkali metal hydrides such as sodium hydride, or alkali metal bicarbonates such as sodium bicarbonate in a suitable solvent.
The inventors have also developed a process for the preparation of the chiral delta- lactone of formula II, wherein R1 represents hydrogen, halogen or an alkoxy group. The process involves cyclizing a chiral hydroxyacid of formula IN in the presence of an acid or a salt of a weak base to obtain the chiral lactone of formula II. Both organic and inorganic acids may be used. Examples of suitable acids include hydrochloric, p-toluenesulfonic, acetic, and methanesulfonic acids. Examples of suitable salts of a weak base include pyridinium p-toluenesulfonate, and pyridine hydrobromide.
The cyclization reaction may be carried out at a temperature from about -20°C to about 120°C, or at a temperature from about 0°C to about 60°C. In particular, it may be carried out at a temperature from about 10°C to about 40°C.
The cyclization reaction may be carried out in a suitable solvent.
The term "suitable solvent" includes any solvent or solvent mixtures which are inert and do not change under the reaction conditions, may be used in the cyclization reactions. Examples of such solvents include ethers such as diethyl ether, dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran; chlorinated hydrocarbons such as methylene dichloride and ethylene dichloride; esters such as ethyl acetate and isopropyl acetate; ketones such as acetone and methylisobutylketone (MLBK); hydrocarbons such as hexane, toluene, and xylene; acetonitrile; dipolar aprotic solvents such as dimethylfoπnamide, dimethylsulphoxide, N-methylpyrrolidone, sulpholane; and mixtures thereof.
The inventors have also developed a process for the preparation of chiral hydroxyacid of formula IN, wherein R1 represents hydrogen, halogen or an alkoxy group. The process involves stereoselectively reducing benzoyl butyrate of formula NI, wherein R1 represents hydrogen, halogen or an alkoxy group, and R is an alkyl group, to obtain chiral hydroxyester of formula N; and hydrolyzing the resulting chiral hydroxyester of formula N.
The stereoselective reduction of the compound of formula NI to the compound of formula N may be achieved by reduction with a chiral reducing agent or by using a reducing agent in the presence of a chiral catalyst.
The chiral reducing agents used for the reduction are those customarily used in organic chemistry. Examples of chiral reducing agents include chiral boranes such as (-)- ι3-chlorodiisopinocampheylborane (DIP-Cl), (S)-BIΝAP, (S)-BINAL-H and compounds of structures as shown below:
Figure imgf000007_0001
Examples of reducing agents include sodium borohydride, sodium cyanoborohydride and a borane complex such as borane-THF, and borane-dimethylsulfide complex.
Examples of chiral catalysts which may be used with the above reducing agents can be the same as the chiral boranes exemplified above as chiral reducing agents.
The addition of a dilute acid, such as hydrochloric acid, followed by extraction with a suitable solvent produces the compounds of formula V. The reduction temperature may be varied depending on the choice of a catalyst and/or a reducing agent employed. For example, the reduction may be carried out at a temperature range from about -80°C to about 100°C, or at a temperature from about -40°C to about 40°C. i particular, it may be carried out at a temperature from about -25°C to about -10°C.
Suitable solvents for reduction of the compounds of formula VI are the customary inert solvents that do not change under the reaction conditions. Examples of such solvents include ethers, such as dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran; chlorinated hydrocarbons such as methylene dichloride and ethylene dichloride; alcohols such as methanol, ethanol and isopropanol; esters such as ethyl acetate and isopropyl acetate; hydrocarbons such as hexane, toluene, and xylene; dipolar aprotic solvents such as dimethylformamide, dimethyl sulphoxide, N-methylpyrrolidone; and mixtures thereof.
The compounds of formula VI can be prepared by conventional esterification of the corresponding acids with suitable alcohols. These acids are known compounds, and can be produced by methods known in the art such as the procedure disclosed in U.S. Patent No. 6,207,822.
The compounds of formula IN and formula N may be isolated during the reaction, or allowed to react further in situ to form the chiral lactone of formula II.
The present invention is further illustrated by the following examples which are provided to be exemplary of the inventions and is not intended to limit the scope of the invention.
Example 1
Preparation of 4-(4-fluorobenzoyl)butyric acid
To a stirred suspension of aluminum chloride (205.85g, 1.54mol) in dichloromethane (500ml) was added a solution of glutaric anhydride (80g, 0.7mol) in dichloromethane (125ml) at 0°C. The reaction mass was stirred for 30minutes and fluorobenzene (67.36g, 0.7mol) was added to the reaction mass slowly. The reaction was monitored for completion by TLC and then poured into ice cold water (2000ml) under stirring and the separated solids were collected by filtration. The solids were dissolved in 3% aqueous sodium hydroxide solution (1100ml) and washed with dichloromethane (300ml). The aqueous layer was acidified to give a precipitate. The solids were filtered and washed with water and vacuum-dried to yield the title product (125g, yield: 85%).
1HNMR (CDC13) δ : 8.027 - 7.98 (m, 2H), 7.17 - 7.11 (m, 2H), 3.067 (t, 2H), 2.52 (t, 2H), 2.14 - 2.04 (m, 2H).
Example 2
Preparation of 4-(4-fluorobenzoyl)butyric acid methyl ester
The 4-(4-fluorobenzoyl)butyric acid (lOOg, 0.476mol) obtained in example 1 was dissolved in 1050ml of methanol and 100ml of 16% methanolic hydrochloric acid was added. The reaction was monitored to completion by TLC and the solvent was evaporated under vacuum. The residue was taken-up in 400ml dichloromethane and washed twice with 250ml of 5% sodium bicarbonate solution and then with 500ml of saturated brine solution. The organic layer was dried over sodium sulfate and evaporated to dryness under reduced pressure. The residue was crystallized from ethyl acetate and hexane to yield the pure product (85.7g, yield: 80%).
1H-NMR (CDC13) δ : 8.01 - 7.97 (m, 2H), 7.15 - 7.10 (m, 2H), 3.66 (s, 3H), 3.03 (t, 2H), 2.45 (t, 2H), 2.11 - 2.02 (m, 2H).
Example 3 Preparation of the (6S)-6-(4-fluorophenyl)tetrahydro-2H-pyran-2-one
To a stirred solution of (-)-/3-chlorodiisopinocampheylborane (121.6g, 0.38mol) in tetrahydrofuran (120ml) at -35°C was added a solution of 4-(4-fluorobenzoyl)butyric acid methyl ester (50g, 0.223mol) in tetrahydrofuran (100ml) in 30 minutes and stirred for about 15hours at -25°C. It was followed by the addition of 105ml water and 260ml methanol at -10°C. The reaction mass was immediately treated with 300ml of 5M NaOH solution at -5°C and stirred for 30 minutes. The reaction mass was then poured into a 500ml mixture of methylene chloride and satd. sodium bicarbonate solution (3:2). The aqueous layer was separated and washed with 200ml of methylene chloride and acidified to pH ~2 at 0°C with 6M hydrochloric acid. The aqueous layer was saturated with sodium chloride and extracted twice with ethyl acetate (200ml). The organic layer was dried over sodium sulfate and evaporated to dryness under reduced pressure. The residue was taken in 11 of toluene and treated with a solution of pyridinium 4-toluenesulfonate (5.7g, lOmol %) dissolved in 200ml methylenechloride. The reaction mixture was stirred at room temperature and monitored to completion (~15h) by TLC and then washed with 200ml water and 200ml 5% sodium bicarbonate solution. The organic layer was dried over sodium sulfate and evaporated to dryness. The residue was crystallized from toluene:hexane mixture to yield 33g (yield: 75%) of the lactone. m.p. : 111.1°C, [OC]D: - 21.8° (25°C, c=l% in methanol)
1H-NMR (CDC13) δ : 7.36 - 7.30 (m, 2H), 7.10 - 7.04 (m, 2H), 5.36 - 5.31 (dd,
1H), 2.72 - 2.55 (m, 2H), 2.19 - 2.13 (m, 1H), 2.05 - 1.96 (m, 2H), 1.88-1.85 (m, 1H)
13CNMR (CDCI3) δ : 18.5, 29.3, 30.4, 80.9, 115.3, 115.6, 127.5, 127.6, 135.5, 160.8, 164.1, 171.1
Example 4
Preparation of trans l-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3-hydroxypropyl]-4-(4- benzyloxyphenyl)-2-azetidinone
To a stirred solution of diisopropylamine( 5.72g, 56.6mmol) in tetrahydrofuran (13.5ml) was added 2.5M solution of n-butyl lithium (22.64ml, 56.6mmol) in hexane slowly at -50°C and stirred for 30 minutes. A solution of (6S)-6-(4- fluorophenyl)tetrahydro-2H-pyran-2-one (5.5g, 28.3 mmol) in tetrahydrofuran (37 ml) was added to the reaction mixture at -50°C in 5 minutes. After about 15 minutes of stirring at - 50°C, DMPU (6ml) was added followed by the addition of a solution of 4- benzyloxybenzylidene-4-fluoroaniline (8.63g, 28.3mmol) in 68.75ml of DMF in about 30 minutes. Stirring was continued for lhr at -50°C and the reaction was quenched with 5.5 ml acetic acid. After 15 minutes stirring, the reaction mass was poured into a chilled mixture of 1M hydrochloric acid (250ml) and ethyl acetate (110ml) under vigorous stirring. The layers were separated and the aqueous layer was extracted with 100ml ethyl acetate. The combined organic layers were washed twice with 100ml of 10%o sodium chloride solution and dried over sodium sulphate. The organic layer was evaporated to dryness under reduced pressure. The residue was chromatographed over silica gel (eluant: Hexane: Ethyl acetate 85:15) to yield 9.5g (yield: 67%) of the title product.
1H NMR (CDC13) δ : 7.40 - 7.21 (m, 1 IH), 7.02 - 6.87 (m, 6H), 5.04 (s, 2H), 4.69 (m, IH), 4.55 (d, IH), 3.11 - 3.04 (m, IH), 2.36 (brs, IH), 2.02 - 1.77 (m, 4H)
Example 5
Preparation of (3S,4R)-1 -(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]- 4-(4-hydroxyphenyl)-2-azetidinone
The intermediate trans l-(4-fluorophenyl)-3-[3(S)-(4-fluorophenyl-3- hydroxypropyl]-4-(4-benzyloxyphenyl)-2-azetidinone (5g, lmmol) was dissolved in 85ml methanol and the solution was deaerated. Ammonium formate (6.3 lg, lOmmol), 10%) palladium on carbon (3.6g) and formic acid (0.5ml) was added to the solution. The reaction was heated to 55°C and monitored to completion by TLC. The reaction mixture was filtered over a filtration aid to remove the 'palladium on carbon' and washed with methanol. Washings of the 'palladium on carbon' were added to the main filtrate. The filtrate was evaporated to dryness, and the residue was dissolved in 100ml dichloromethane and washed with 10% sodium chloride solution. The dichloromethane layer was then evaporated to dryness under vacuum. The residue (3.74g) so obtained was dissolved in ethyl acetate (7.5ml) at room temperature and 60 ml of tert.-butyl methyl ether was added slowly to it. The resulting suspension was stirred for lhr and the solids obtained were filtered to obtain the title compound as a tert.-butyl methyl ether solvate. Yield: 1.76g, Chiral purity (by HPLC): 99.69%.
1H NMR (DMSO) δ : 9.52 (s, IH), 7.36 - 7.08 (m, 10H), 6.76 - 6.74 (d, 2H), 5.30 - 5.29 (d, IH), 4.77 (s, IH), 4.56 - 4.55 (m, IH), 3.08 (s, 4H), 1.88 - 1.72 (m, 4H), 1.11 (s, 9H).
The above solvate was dissolved in methanol, and a precipitate was obtained by addition of water to the solution. The solid was filter and dried to obtain the title compound (1.5 g).
1H NMR (DMSO) δ : 9.49 (s, IH), 7.35 - 7.07 (m, 10H), 6.76 - 6.73 (d, 2H), 5.28 - 5.27 (d, IH), 4.77 (s, IH), 4.56 - 4.54 ( , IH), 3.08 - 3.06 (m, IH), 1.87 - 1.72 (m, 4H). Example 6
Preparation of Ezetimibe- (3R,4S)-l-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3- hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone
The filtrate obtained in Example 5 above after filtering off the solids was concentrated under vacuum. The residue was dissolved in 4ml ethyl acetate and 4ml n- hexane was added to it. The mixture was stirred for 2 hours and the crystals obtained were collected by filtration to yield, after drying, the title compound (0.8 g, yield: 19.5%). m.p.: 161 Λ°C, [α]D: -28.7° (25°C, c=0.34% in methanol)
1H NMR (DMSO) δ : 9.50 (s, IH), 7.32 - 7.07 (m, 10H), 6.76 - 6.74 (d, 2H), 5.27 - 5.26 (d, IH), 4.79 (s, IH), 4.50 - 4.48 (m, IH), 3.07 - 3.05 (m, IH), 1.83 - 1.72 (m, 4H).
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

Claims

We claim:
1. A process for the preparation of trans-isomers of diphenylazetidinone of formula I, or a salt thereof,
Figure imgf000013_0001
Formula I
1 wherein R and R are identical or different, and represent hydrogen, halogen or an alkoxy group, and R3 represents hydrogen, alkyl or a hydroxy protecting group, the process comprising reacting a chiral delta-lactone of formula II,
Figure imgf000013_0002
Formula II
wherein R1 is as defined above, with a diphenyl imine of formula III,
Figure imgf000013_0003
Formula III wherein R2, and R3 are as defined above, in the presence of a base.
2. The process of claim 1 , wherein R1 and R2 represent fluorine and R3 represents hydrogen.
3. The process of claim 1 , wherein the base comprises one or more of alkyl lithium, metal hydride, metal alkoxide, and metal amide.
4. The process of claim 3, wherein the metal amide comprises one or more of sodium bistrimethylsilylamide, potassium bistrimethylsilylamide, lithium bistrimethylsilylamide, lithium diisopropylamide and lithium dicyclohexylamide.
5. The process of claim 1, wherein the reaction is carried out at a temperature of from about -80°C to about 0°C.
6. The process of claim 5, wherein the reaction is carried out at a temperature of from about -60°C to about -40°C.
7. The process of claim 1, wherein the reaction is carried out in a solvent.
8. The process of claim 7, wherein the solvent comprises one or more of hydrocarbons, chlorinated hydrocarbons, ethers, dipolar aprotic solvents, and mixtures thereof.
9. The process of claim 8, wherein the ether comprises one or more of dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran (THF).
10. The process of claim 8, wherein the chlorinated hydrocarbon comprises one or more of methylene dichloride and ethylene dichloride
11. The process of claim 8, wherein the hydrocarbon comprises one or more of hexane, cyclohexane, toluene, and xylene.
12. The process of claim 8, wherein the dipolar aprotic solvents comprises one or more of dimethylformamide, dimethylsulphoxide, and N-methylpyrrolidone.
13. The process of claim 7, wherein a cosolvent is used.
14. The process of claim 13, wherein the cosolvent comprises one or more of hexamethylphosphoramide (HMPA), Hexamethyl phosphorous triamide (HMPT), N,N-dimethylimidazolidinone (DMI) and l,3-dimethyl-3,4,5,6-tetrahydro-2-(lH)- pyrimidinone (DMPU).
15. A process for the preparation of chiral delta-lactone of formula II,
Figure imgf000015_0001
Formula II
wherein R1 is hydrogen, halogen or an alkoxy group, the process comprising cyclizing a chiral hydroxyacid of formula IN,
Figure imgf000015_0002
Formula IV
wherein R1 is as defined above, in the presence of an acid or a salt of a weak base.
16. The process of claim 15, wherein R1 is fluorine.
17. The process of claim 15, wherein the acid comprises one or more of hydrochloric, p-toluenesulfonic, acetic, and methanesulfonic acids.
18. The process of claim 15, wherein the salt of a weak base comprises one or more of pyridinium p-toluenesulfonate, and pyridine hydrobromide.
19. The process of claim 15, wherein the reaction is carried out at a temperature of from about 0°C to about 60°C.
20. The process of claim 15, wherein the reaction is carried out in a solvent.
21. The process of claim 20, wherein the solvent comprises one or more of ethers, chlorinated hydrocarbons, esters, ketones, hydrocarbons, acetonitrile, dipolar aprotic solvents and mixtures thereof.
22. The process of claim 21, wherein the chlorinated hydrocarbon comprises one or more of methylene dichloride and ethylene dichloride.
23. The process of claim 21, wherein the hydrocarbon comprises one or more of hexane, toluene, and xylene.
24. The process of claim 21, wherein the ether comprises one or more of diethyl ether, dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran (THF).
25. The process of claim 21, wherein the ester comprises one or more of ethyl acetate and isopropyl acetate.
26. The process of claim 21 , wherein the ketone comprises one or more of acetone and methylisobutylketone.
27. The process of claim 21, wherein the dipolar aprotic solvents comprises one or more of dimethylformamide, dimethylsulphoxide, and N-methylpyrrolidone.
28. A process for the preparation of the chiral hydroxyacid of formula IV,
Figure imgf000016_0001
Formula IV
wherein R1 is hydrogen, halogen or an alkoxy group,
the process comprising stereoselectively reducing benzoyl butyrate of formula VI,
Figure imgf000017_0001
Formula VI
wherein R1 is as defined above and R is an alkyl group to obtain chiral hydroxyester of formula V,
Figure imgf000017_0002
Formula V
wherein R1 and R are as defined above; and hydrolyzing the chiral hydroxyester to obtain the chiral hydroxyacid of formula IN.
29. The process of claim 28, wherein the reduction comprises using a chiral reducing agent.
30. The process of claim 28, wherein the reduction comprises using a reducing agent in the presence of a chiral catalyst.
31. The process of claim 30, wherein the reducing agent comprises one or more of sodium borohydride, sodium cyanoborohydride, borane-THF, and borane- dimethylsulfide.
32. The process of claim 29 or 30, wherein the chiral reducing agent or the chiral catalyst is a chiral borane.
33. The process of claim 32, wherein the chiral borane comprises one or more of (~)-β- chlorodiisopinocampheylborane (DIP-Cl), (S)-BLNAP, (S)-BLNAL-H and compounds of structures as shown below.
Figure imgf000018_0001
34. The process of claim 28, wherein the reduction is carried out at a temperature of from about -40°C to about 40°C.
35. The process of claim 28, wherein the reduction is carried out in a solvent.
36. The process of claim 35, wherein the solvent comprises one or more of ethers, chlorinated hydrocarbons, esters, hydrocarbons, alcohols, dipolar aprotic solvents and mixtures thereof.
37. The process of claim 36, wherein the ether comprises one or more of dibutyl ether, methyl tert-butyl ether, dioxane and tetrahydrofuran(THF).
38. The process of claim 36, wherein the chlorinated hydrocarbon comprises one or more of methylene dichloride and ethylene dichloride.
39. The process of claim 36, wherein the hydrocarbon comprises one or more of hexane, toluene and xylene.
40. The process of claim 36, wherein the ester comprises one or more of ethyl acetate and isopropyl acetate.
41. The process of claim 36, wherein the alcohol comprises one or more of methanol, ethanol and isopropanol.
42. The process of claim 36, wherein the dipolar aprotic solvents comprises one or more of dimethylformamide, dimethylsulphoxide, and N-methylpyrrolidone.
43. A pharmaceutical composition comprising a therapeutically effective amount of a trans-isomer of a diphenylazetidinone derivative or a pharmaceutically acceptable salt thereof obtained by the process of claim 1; and one or more pharmaceutically acceptable carriers, excipients or diluents.
PCT/IB2004/001396 2003-05-05 2004-05-05 Process for the preparation of trans-isomers of diphenylazetidinone derivatives WO2004099132A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04731224A EP1626954A2 (en) 2003-05-05 2004-05-05 Process for the preparation of trans-isomers of diphenylazetidinone derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN668DE2003 2003-05-05
IN668/DEL/2003 2003-05-05

Publications (2)

Publication Number Publication Date
WO2004099132A2 true WO2004099132A2 (en) 2004-11-18
WO2004099132A3 WO2004099132A3 (en) 2005-03-24

Family

ID=33428285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001396 WO2004099132A2 (en) 2003-05-05 2004-05-05 Process for the preparation of trans-isomers of diphenylazetidinone derivatives

Country Status (4)

Country Link
EP (1) EP1626954A2 (en)
CN (1) CN1805926A (en)
AR (1) AR044177A1 (en)
WO (1) WO2004099132A2 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060808A1 (en) * 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
WO2006122020A2 (en) 2005-05-06 2006-11-16 Microbia, Inc. Process for production of 4-biphenylyazetidin-2-ones
WO2006127893A2 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2007017705A1 (en) * 2005-08-09 2007-02-15 Glenmark Pharmaceuticals Limited Process for the preparation of azetidinones
EP1885703A2 (en) * 2005-05-11 2008-02-13 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
WO2008061238A2 (en) * 2006-11-16 2008-05-22 Ironwood Pharmaceuticals, Inc. Processes for production of 4-biphenylyazetidin-2-ones
US7470678B2 (en) 2002-07-05 2008-12-30 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
EP2128133A1 (en) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
US7863265B2 (en) 2005-06-20 2011-01-04 Astrazeneca Ab 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7906502B2 (en) 2005-06-22 2011-03-15 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US20110166237A1 (en) * 2008-06-02 2011-07-07 Cipla Limited Process for the Synthesis of Arformoterol
WO2012173504A2 (en) 2011-06-15 2012-12-20 Instytut Chemii Organicznej Polskiej Akademii Nauk Method for synthesis of the substituted azetidinones and intermediates for their synthesis
WO2013189646A1 (en) * 2012-06-22 2013-12-27 Henkel Ag & Co. Kgaa Photolabile pro-fragrances
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
CN108586373A (en) * 2018-06-22 2018-09-28 苏州市贝克生物科技有限公司 The synthetic method of Ezetimibe intermediate

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103086938A (en) * 2011-10-28 2013-05-08 沈阳药科大学 Ezetimibe synthesis method
CN103121966A (en) * 2011-11-17 2013-05-29 重庆华邦胜凯制药有限公司 Method for directionally synthesizing (4-chlorphenyl)-(pyridine-2-base)-methanol
CN103204795B (en) * 2012-01-11 2016-12-14 重庆华邦胜凯制药有限公司 A kind of preparation method of chirality azetidinones
CN104744331B (en) * 2013-12-31 2018-05-15 浙江九洲药业股份有限公司 A kind of synthesis technique of Ezetimible intermediate
CN107176920B (en) * 2017-04-19 2019-09-20 江苏恒盛药业有限公司 A kind of new technique for synthesizing of ezetimibe
CN110818606B (en) * 2018-08-08 2021-06-29 上海博志研新药物技术有限公司 Preparation method of ezetimibe and intermediate thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOWNHAM R ET AL: "Dispiroketals in Synthesis (Part 19)<1>: Dispiroketals as Enantioselective and Regioselective Protective Agents for Symmetric Cyclic and Acyclic Polyols" TETRAHEDRON: ASYMMETRY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 6, no. 10, 1 October 1995 (1995-10-01), pages 2403-2440, XP004047992 ISSN: 0957-4166 *
ROSENBLUM S B ET AL: "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl )-(3S)- hydroxypropylÜ-(4S)-(4-hydroxyphenyl)-2-az etidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, 1998, pages 973-980, XP002275926 ISSN: 0022-2623 *
WU G. ET AL.: "A novel one-step diastereo- and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors" JOURNAL OF ORGANIC CHEMISTRY, vol. 64, 1999, pages 3714-3718, XP002296009 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470678B2 (en) 2002-07-05 2008-12-30 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
WO2006060808A1 (en) * 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
JP2007526251A (en) * 2004-12-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド Ezetimibe polymorph
WO2006122020A2 (en) 2005-05-06 2006-11-16 Microbia, Inc. Process for production of 4-biphenylyazetidin-2-ones
WO2006122020A3 (en) * 2005-05-06 2007-05-18 Microbia Inc Process for production of 4-biphenylyazetidin-2-ones
EP1885703A4 (en) * 2005-05-11 2009-09-02 Microbia Inc Processes for production of phenolic 4-biphenylylazetidin-2-ones
EP1885703A2 (en) * 2005-05-11 2008-02-13 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
WO2006127893A3 (en) * 2005-05-25 2007-03-08 Microbia Inc Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2006127893A2 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
US7863265B2 (en) 2005-06-20 2011-01-04 Astrazeneca Ab 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7906502B2 (en) 2005-06-22 2011-03-15 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2007017705A1 (en) * 2005-08-09 2007-02-15 Glenmark Pharmaceuticals Limited Process for the preparation of azetidinones
WO2008061238A3 (en) * 2006-11-16 2008-09-25 Ironwood Pharmaceuticals Inc Processes for production of 4-biphenylyazetidin-2-ones
WO2008061238A2 (en) * 2006-11-16 2008-05-22 Ironwood Pharmaceuticals, Inc. Processes for production of 4-biphenylyazetidin-2-ones
EP2128133A1 (en) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
WO2009150038A1 (en) 2008-05-26 2009-12-17 Lek Pharmaceuticals D.D. Process for the preparation of ezetimibe and composition containing it
CN102066318A (en) * 2008-05-26 2011-05-18 力奇制药公司 Process for the preparation of ezetimibe and composition containing it
US20110166237A1 (en) * 2008-06-02 2011-07-07 Cipla Limited Process for the Synthesis of Arformoterol
US9029421B2 (en) * 2008-06-02 2015-05-12 Cipla Limited Process for the synthesis of arformoterol
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
WO2012173504A2 (en) 2011-06-15 2012-12-20 Instytut Chemii Organicznej Polskiej Akademii Nauk Method for synthesis of the substituted azetidinones and intermediates for their synthesis
WO2013189646A1 (en) * 2012-06-22 2013-12-27 Henkel Ag & Co. Kgaa Photolabile pro-fragrances
US9458081B2 (en) 2012-06-22 2016-10-04 Henkel Ag & Co. Kgaa Photolabile pro-fragrances
CN108586373A (en) * 2018-06-22 2018-09-28 苏州市贝克生物科技有限公司 The synthetic method of Ezetimibe intermediate

Also Published As

Publication number Publication date
WO2004099132A3 (en) 2005-03-24
EP1626954A2 (en) 2006-02-22
CN1805926A (en) 2006-07-19
AR044177A1 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
WO2004099132A2 (en) Process for the preparation of trans-isomers of diphenylazetidinone derivatives
EP0906278B1 (en) 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
JPWO2006006496A1 (en) Method for producing azulene derivatives and synthetic intermediates thereof
RU2650687C1 (en) Method for obtaining azetidinone compounds and derivatives of azetidinone compounds
US5149838A (en) Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
WO2009067960A2 (en) A method of manufacturing (3r,4s)-l-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3- hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone and its intermediates
JPH0557980B2 (en)
CN110869380A (en) Process for preparing SGLT2 inhibitors and intermediates thereof
JP2003535077A (en) Method for producing indole derivative and intermediate of the method
WO2012140490A2 (en) Process for preparing quinoline derivative
JP2617960B2 (en) Stereoisomerization method for producing optically active carboxylic acids
JPS6328423B2 (en)
JP3748933B2 (en) Process for producing 1-substituted azetidinone derivatives
US7642370B2 (en) Method for preparing prostaglandin derivative
JP2641363B2 (en) Novel phenethyl alcohol and its production method
CN117003630A (en) Methods and intermediates for preparing carboprostacyclin analogs
JP3529425B2 (en) Method for producing (S) -3-lower alkyl-2-piperazinone
JP4947996B2 (en) Cedanolide production method
US4018797A (en) Intermediates for prostaglandins
MATSUMURA et al. Synthetic Studies of Carbapenem and Penem Antibiotics. VI. Stereoselective Reduction of Enamino Ketone and Lactonization of the Reduction Product for the Synthesis of 1β-Methylcarbapenem
US4758666A (en) Process for the preparation of an apovincaminol derivative
KR20160098495A (en) Process for the preparation of empagliflozin
JP2003055357A (en) Method for producing 3,4-epoxybutanoic acid ester
EP2014650A1 (en) Process and intermediate for the production of an intermediate in the production of montelukast
JP3799722B2 (en) Method for producing enol thioether

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004731224

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5651/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20048162566

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004731224

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004731224

Country of ref document: EP